473 related articles for article (PubMed ID: 17572079)
21. High incidence of BRCA1-2 germline mutations, previous breast cancer and familial cancer history in Jewish patients with uterine serous papillary carcinoma.
Biron-Shental T; Drucker L; Altaras M; Bernheim J; Fishman A
Eur J Surg Oncol; 2006 Dec; 32(10):1097-100. PubMed ID: 16650962
[TBL] [Abstract][Full Text] [Related]
22. Three germline mutations in the TP53 gene.
Cornelis RS; van Vliet M; van de Vijver MJ; Vasen HF; Voute PA; Top B; Khan PM; Devilee P; Cornelisse CJ
Hum Mutat; 1997; 9(2):157-63. PubMed ID: 9067756
[TBL] [Abstract][Full Text] [Related]
23. Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil.
Palmero EI; Schüler-Faccini L; Caleffi M; Achatz MI; Olivier M; Martel-Planche G; Marcel V; Aguiar E; Giacomazzi J; Ewald IP; Giugliani R; Hainaut P; Ashton-Prolla P
Cancer Lett; 2008 Mar; 261(1):21-5. PubMed ID: 18248785
[TBL] [Abstract][Full Text] [Related]
24. No germline mutations in the histone acetyltransferase gene EP300 in BRCA1 and BRCA2 negative families with breast cancer and gastric, pancreatic, or colorectal cancer.
Campbell IG; Choong D; Chenevix-Trench G;
Breast Cancer Res; 2004; 6(4):R366-71. PubMed ID: 15217503
[TBL] [Abstract][Full Text] [Related]
25. Hereditary breast cancer syndromes in a Turkish population. Results of molecular germline analysis.
Güran S; Ozet A; Dede M; Gille JJ; Yenen MC
Cancer Genet Cytogenet; 2005 Jul; 160(2):164-8. PubMed ID: 15993273
[TBL] [Abstract][Full Text] [Related]
26. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families.
Achatz MI; Olivier M; Le Calvez F; Martel-Planche G; Lopes A; Rossi BM; Ashton-Prolla P; Giugliani R; Palmero EI; Vargas FR; Da Rocha JC; Vettore AL; Hainaut P
Cancer Lett; 2007 Jan; 245(1-2):96-102. PubMed ID: 16494995
[TBL] [Abstract][Full Text] [Related]
27. [Germline mutations in the BRCA1 and BRCA2 genes from breast cancer families in China Han people].
Zhou YZ; Sun Q; Lin SQ; Wang J; Liu B; Li JX; Zhou YD; Ye J; Han H; Fang FD
Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):294-8. PubMed ID: 15059511
[TBL] [Abstract][Full Text] [Related]
28. The prevalence of BRCA1 and BRCA2 germline mutations in high-risk breast cancer patients of Chinese Han nationality: two recurrent mutations were identified.
Li WF; Hu Z; Rao NY; Song CG; Zhang B; Cao MZ; Su FX; Wang YS; He PQ; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Liu XY; Zhou J; Wang L; Zhao L; Liu YB; Yuan WT; Yang L; Shen ZZ; Huang W; Shao ZM
Breast Cancer Res Treat; 2008 Jul; 110(1):99-109. PubMed ID: 17851763
[TBL] [Abstract][Full Text] [Related]
29. Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.
Cao AY; Huang J; Hu Z; Li WF; Ma ZL; Tang LL; Zhang B; Su FX; Zhou J; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Yuan WT; Shen ZZ; Huang W; Shao ZM
Breast Cancer Res Treat; 2009 May; 115(1):51-5. PubMed ID: 18483852
[TBL] [Abstract][Full Text] [Related]
30. Identification of novel TP53 mutations in familial and sporadic cancer cases of German and Swiss origin.
Bendig I; Mohr N; Kramer F; Weber BH
Cancer Genet Cytogenet; 2004 Oct; 154(1):22-6. PubMed ID: 15381368
[TBL] [Abstract][Full Text] [Related]
31. [When is it useful to look for TP53 germline gene mutations in families of oncology patients?].
Trková M; Sedlácek Z
Cas Lek Cesk; 2003; 142(4):220-5. PubMed ID: 12841124
[TBL] [Abstract][Full Text] [Related]
32. [Li-Fraumeni syndrome].
Frebourg T
Bull Cancer; 1997 Jul; 84(7):735-40. PubMed ID: 9339200
[TBL] [Abstract][Full Text] [Related]
33. [Germline mutations of the p53 gene].
Frebourg T
Pathol Biol (Paris); 1997 Dec; 45(10):845-51. PubMed ID: 9769948
[TBL] [Abstract][Full Text] [Related]
34. Can genetic testing guide treatment in breast cancer?
Tutt A; Ashworth A
Eur J Cancer; 2008 Dec; 44(18):2774-80. PubMed ID: 19027287
[TBL] [Abstract][Full Text] [Related]
35. Beyond Li Fraumeni Syndrome: clinical characteristics of families with p53 germline mutations.
Gonzalez KD; Noltner KA; Buzin CH; Gu D; Wen-Fong CY; Nguyen VQ; Han JH; Lowstuter K; Longmate J; Sommer SS; Weitzel JN
J Clin Oncol; 2009 Mar; 27(8):1250-6. PubMed ID: 19204208
[TBL] [Abstract][Full Text] [Related]
36. BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study.
Musolino A; Bella MA; Bortesi B; Michiara M; Naldi N; Zanelli P; Capelletti M; Pezzuolo D; Camisa R; Savi M; Neri TM; Ardizzoni A
Breast; 2007 Jun; 16(3):280-92. PubMed ID: 17257844
[TBL] [Abstract][Full Text] [Related]
37. Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms.
Malkin D; Jolly KW; Barbier N; Look AT; Friend SH; Gebhardt MC; Andersen TI; Børresen AL; Li FP; Garber J
N Engl J Med; 1992 May; 326(20):1309-15. PubMed ID: 1565144
[TBL] [Abstract][Full Text] [Related]
38. High incidence of protein-truncating TP53 mutations in BRCA1-related breast cancer.
Holstege H; Joosse SA; van Oostrom CT; Nederlof PM; de Vries A; Jonkers J
Cancer Res; 2009 Apr; 69(8):3625-33. PubMed ID: 19336573
[TBL] [Abstract][Full Text] [Related]
39. The prevalence of PALB2 germline mutations in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.
Cao AY; Huang J; Hu Z; Li WF; Ma ZL; Tang LL; Zhang B; Su FX; Zhou J; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Yuan WT; Shen ZZ; Huang W; Shao ZM
Breast Cancer Res Treat; 2009 Apr; 114(3):457-62. PubMed ID: 18446436
[TBL] [Abstract][Full Text] [Related]
40. Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype.
Olivier M; Goldgar DE; Sodha N; Ohgaki H; Kleihues P; Hainaut P; Eeles RA
Cancer Res; 2003 Oct; 63(20):6643-50. PubMed ID: 14583457
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
